Passage Bio, Inc. (PASG)
Largest Insider Buys in Sector
PASG Stock Price History Chart
PASG Stock Performance
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the …
Insider Activity of Passage Bio, Inc.
Over the last 12 months, insiders at Passage Bio, Inc. have bought $284,520 and sold $345,462 worth of Passage Bio, Inc. stock.
On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $18.87M and sold $278,880 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $569,039.
The last purchase of 29,300 shares for transaction amount of $19,663 was made by Lynx1 Capital Management LP (10 percent owner) on 2024‑11‑27.
List of Insider Buy and Sell Transactions, Passage Bio, Inc.
| 2024-12-11 | Sale | 10 percent owner | 80 0.0001% | $0.80 | $64 | -4.75% | ||
| 2024-12-10 | Sale | 10 percent owner | 8,015 0.013% | $0.80 | $6,412 | -6.62% | ||
| 2024-12-09 | Sale | 10 percent owner | 54,181 0.0924% | $0.84 | $45,512 | -5.25% | ||
| 2024-12-06 | Sale | 10 percent owner | 20,903 0.0352% | $0.82 | $17,140 | -2.13% | ||
| 2024-12-04 | Sale | 10 percent owner | 76,200 0.1269% | $0.79 | $60,198 | +1.35% | ||
| 2024-11-27 | 10 percent owner | 29,300 0.0467% | $0.67 | $19,663 | +15.06% | |||
| 2024-11-26 | 10 percent owner | 167,055 0.2621% | $0.71 | $118,191 | +1.07% | |||
| 2024-11-25 | 10 percent owner | 259,998 0.3493% | $0.56 | $146,665 | +22.14% | |||
| 2024-09-19 | Sale | 10 percent owner | 39,300 0.0645% | $0.71 | $27,903 | -7.43% | ||
| 2024-09-18 | Sale | 10 percent owner | 25,631 0.0432% | $0.73 | $18,711 | -7.50% | ||
| 2024-09-17 | Sale | 10 percent owner | 111,400 0.181% | $0.73 | $81,322 | -10.77% | ||
| 2024-09-16 | Sale | 10 percent owner | 63,100 0.1035% | $0.74 | $46,694 | -11.16% | ||
| 2024-02-13 | Sale | CHIEF MEDICAL OFFICER | 1,638 0.0029% | $0.97 | $1,589 | -4.14% | ||
| 2024-02-13 | Sale | SVP, INTERIM CFO | 1,470 0.0026% | $0.97 | $1,426 | -4.14% | ||
| 2024-01-02 | Sale | GC & Corporate Secretary | 15,813 0.0291% | $0.91 | $14,390 | +6.36% | ||
| 2024-01-02 | Sale | Chief Medical Officer | 15,813 0.0291% | $0.91 | $14,390 | +6.36% | ||
| 2024-01-02 | Sale | SVP, Interim CFO | 10,672 0.0197% | $0.91 | $9,712 | +6.36% | ||
| 2023-07-28 | Sale | Chief Financial Officer | 11,453 0.021% | $0.88 | $10,079 | +5.64% | ||
| 2023-06-28 | 10 percent owner | 575,195 1.0841% | $0.84 | $483,164 | +14.66% | |||
| 2023-06-27 | 10 percent owner | 617,382 1.144% | $0.84 | $518,601 | +12.39% |
Insider Historical Profitability
| Lynx1 Capital Management LP | 10 percent owner | 8883308 14.3819% | $0.66 | 3 | 0 | |
| ORBIMED ADVISORS LLC | 10 percent owner | 7635190 12.3612% | $0.66 | 10 | 9 | <0.0001% |
| Cale Edgar B. | GC & Corporate Secretary | 45995 0.0745% | $0.66 | 1 | 1 | <0.0001% |
| OrbiMed Capital GP VII LLC | 6537923 10.5848% | $0.66 | 1 | 0 | <0.0001% | |
| Heron Patrick J | 5009219 8.1098% | $0.66 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $13.67M | 16.43 | 10.12M | 0% | +$0 | 0.11 | |
| Versant Ventures | $6.7M | 8.05 | 4.96M | 0% | +$0 | 6.49 | |
| Lynx1 Capital Management Lp | $6.54M | 7.86 | 4.85M | +1,178.06% | +$6.03M | 0.35 | |
| New Leaf Venture Partners | $3.37M | 4.05 | 2.5M | 0% | +$0 | 3.21 | |
| The Vanguard Group | $2.8M | 3.36 | 2.07M | +2.61% | +$71,085.59 | <0.0001 |